Indications -- Lupus/Nephritis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who started this subject	12/3/2002 5:50:55 PM
From: nigel bates	of 95

ZGEN / TACI-Ig ZymoGenetics Highlights Development Programs at Analyst & Investor Briefing Message 18297281 ...Development Program Summaries TACI-Ig One of the Company's lead product opportunities is TACI-Ig, a soluble fusion protein that links part of a novel cytokine receptor (TACI) to the Fc portion of immunoglobulin (Ig). This product candidate is being developed as a therapy for autoimmune diseases that result from inappropriate activity of B-lymphocytes, and the production of autoantibodies, antibodies that attack an individual's own healthy tissues. Such diseases include SLE, rheumatoid arthritis and idiopathic thrombocytopenia purpura, among others. TACI-Ig has been demonstrated to bind to and neutralize the activity of BLyS, a cytokine that stimulates B-cell proliferation, and the induction of antibody production. The determination that over-expression of BLyS correlates with the onset and severity of autoimmune disease in animal models, and the observation that elevated levels of BLyS are present in the serum of patients with SLE and various other autoimmune diseases, suggests that an antagonist to BLyS may have therapeutic utility. ZymoGenetics researchers have produced TACI-Ig, an antagonist protein that can "mop up" increased BLyS present in the blood. In an animal model of SLE, treatment with TACI-Ig was effective in limiting the onset and progression of the disease. Similar positive results were observed with TACI-Ig in a mouse model of arthritis. These data suggest that TACI-Ig may provide a novel approach to treat autoimmune disease. ZymoGenetics has entered into an exclusive co-development and commercialization agreement with Serono for the development of TACI-Ig, for the treatment of various autoimmune diseases. ZymoGenetics and Serono intend to initiate clinical studies with TACI-Ig in the second half of 2003 with SLE as the first indication...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next